Effect of sacubitril/valsartan in Moroccan patients with Chronic Heart Failure

Abstract

Chronic heart failure became more frequent in Moroccan patients. The aim of our study is to determinate the benefit of saccubitril/valartan in patients with chronic heart failure. It's a prospective study included 80 patients with chronic heart failure with reduced ejection fraction (HFrEF), admitted in Cardiac Rehabilitation unit, Cardiology centre, Mohammed V Military Hospital of Rabat, Morocco. All of them had clinical evaluation, echocardiography and cardio respiratory capacities evaluation. The average age of patients was 68,43 ± 8,4 years with male predominance, they have more than three cardiovascular risk factors dominated by smoking and hypertension, coronary artery disease is the most frequent etiology, they had reduced ejection fraction (EF: 34 ± 7,2%). After 20 sessions of exercise training and therapeutic education specially optimisation of treatment by introducing precociously of saccubitril/valsartan and increasing doses gradually along the program, patients have a good quality of life, they become less symptomatic (dyspnea class III to II of NYHA); they significantly improve maximal work load (from 55, 6 ± 11,9 to 67, 2 ± 21,8 watt) and VO2max (from 13,1 ± 5,1 to 19,4 ± 7,4 ml/kg/min) This study demonstrated that exercise training and optimisation of treatment specially saccubril/valsartan is clearly benefit for patients with chronic heart failure to improve their exercise capacities and quality of life.